Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rare, aggressive NSCLC type yields to pembrolizumab

Key clinical point: Pulmonary sarcomatoid carcinomas are extremely sensitive to anti–programmed death-ligand 1 therapy.

Major finding: The objective response rate was 80% and clinical benefit rate was100%.

Study details: A retrospective case series of five patients plus historical patients for comparison purposes.

Disclosures: The study was internally funded. Dr. Sukrithan reported having no disclosures.

Citation:

Sukrithan V et al. ASCO-SITC, Abstract 115.